Silexion Therapeutics Corp
SLXN
Analytical Summary
On an absolute basis, Silexion Therapeutics Corp shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
3-Year Financial Trajectory
Annualinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Invested CapitalReturn on Invested Capital of -447.0% is weak on an absolute basis (target > 10%)
- Interest CoverageInterest Coverage of -894.77x is weak on an absolute basis (target > 5x)
- FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| EPS Growth YoY (%) |
-97.7%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
792.9%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— |
| Net Income Growth YoY (%) |
27.9%
Excellent
Excellent
Year-over-year change in net income |
-223.4%
Weak
Weak
Year-over-year change in net income |
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Effective Tax Rate (%) (%) |
-0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.1%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.6%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
| FCF / Net Income (x) |
0.91x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.51x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.89x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Return on Invested Capital (%) |
-447.0%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
315.3%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
30.4%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
| Return on Capital (%) (%) |
-161.2%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-439.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-89.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
| Return on Common Equity (%) (%) | — | — |
33.0%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+120%)
|
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Interest Coverage (x) |
-894.77x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
-465.59x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
| Net Debt (USD) | $-5.99M | $-1.19M | $-4.59M |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare SLXN with peers
Stack SLXN against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 12 quarters